Company research
iSpecimen Inc.
CIK 1558569Updated Nov 6, 2026
SecurityISPC · NASDAQ · equity
ISPC price & chart
Loading TradingView…
NASDAQ:ISPC on TradingView ↗About the company
iSpecimen is a technology-driven company founded to address a critical challenge: how to connect life science researchers who need human biofluids, tissues, and living cells (“biospecimens”) for their research, with the billions of biospecimens available (but not easily accessible) in healthcare provider organizations worldwide. Our ground-breaking iSpecimen Marketplace platform was designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery.
In the news
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants ↗
Recent filings
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Changes in Control of Registrant · Regulation FD Disclosure
Items 1.01, 2.01, 3.02, 5.01, 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
PRE 14A filing
DEFR14A filing
PRER14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 8,997,557Source | 11,264,223Source | 7,393,201Source | 6,034,501Source | 11,901,858Source | 6,609,658Source | 6,843,256Source | 12,513,901Source | 9,531,410Source | 9,350,230Source | 15,819,137Source | 24,617,653Source |
| Property, Plant and Equipment, NetUSD | 42,666Source | 102,803Source | 21,011Source | 59,789Source | 104,822Source | 23,134Source | 76,460Source | 120,873Source | 25,543Source | 93,563Source | 127,787Source | 225,852Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 1,751,854Source | 4,414,364Source | — | 2,151,243Source | 2,818,989Source | — | 2,089,891Source | 6,880,835Source | 1,878,408Source | 2,343,666Source | 15,308,710Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 120,931Source | 974,383Source | 21,257Source | 372,469Source | 892,814Source | 132,848Source | 581,652Source | 437,424Source | 48,298Source | 1,444,636Source | 728,388Source | 1,597,915Source |
| Assets, CurrentUSD | 3,601,811Source | 4,657,835Source | 4,484,562Source | 1,166,170Source | 5,235,253Source | 3,484,029Source | 1,528,038Source | 5,285,951Source | 6,954,590Source | 3,587,936Source | 8,238,603Source | 19,675,721Source |
| Prepaid Expense and Other Assets, CurrentUSD | 698,122Source | 277,579Source | 48,941Source | 204,926Source | 237,564Source | 532,192Source | 163,823Source | 313,999Source | 25,457Source | 264,892Source | 292,079Source | 300,434Source |
| Operating Lease, Right-of-Use AssetUSD | 284,146Source | 342,107Source | 238,390Source | 299,001Source | 26,538Source | 253,914Source | 313,610Source | 153,340Source | 269,160Source | 327,977Source | 193,857Source | 184,692Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 5,924,846Source | 6,549,651Source | 5,656,821Source | 5,412,528Source | 5,812,574Source | 5,795,620Source | 5,174,743Source | 5,700,673Source | 6,443,179Source | 6,039,222Source | 6,078,060Source | 4,308,483Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 977Source | 83Source | 152Source | 250Source | 1,309Source | 2,967Source | 250Source | 947Source | 848Source | 170Source | 908Source | 892Source |
| Additional Paid in CapitalUSD | — | 70,530,467Source | 87,724,581Source | — | 70,464,100Source | 85,436,613Source | — | 69,079,341Source | 85,437,703Source | 75,173,627Source | 69,104,313Source | 68,573,774Source |
| Retained Earnings (Accumulated Deficit)USD | -77,348,904Source | -65,815,806Source | -85,988,181Source | -74,568,256Source | -64,375,953Source | -84,625,370Source | -73,521,013Source | -62,266,929Source | -82,350,149Source | -71,862,617Source | -59,364,812Source | -48,265,324Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | 41Source | — | — | 840Source | — |
| Stockholders' Equity Attributable to ParentUSD | 3,072,711Source | 4,714,572Source | 1,736,380Source | 621,973Source | 6,089,284Source | 814,038Source | 1,668,513Source | 6,813,228Source | 3,088,231Source | 3,311,008Source | 9,741,077Source | 20,309,170Source |
| Liabilities and EquityUSD | 8,997,557Source | 11,264,223Source | 7,393,201Source | 6,034,501Source | 11,901,858Source | 6,609,658Source | 6,843,256Source | 12,513,901Source | 9,531,410Source | 9,350,230Source | 15,819,137Source | 24,617,653Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,698,314Source | 6,268,214Source | 5,477,100Source | 5,171,625Source | 5,812,574Source | 5,599,663Source | 4,919,754Source | 5,700,673Source | 6,231,306Source | 5,770,424Source | 6,048,930Source | 4,281,087Source |
| Operating Lease, Liability, CurrentUSD | 54,904Source | 42,513Source | 61,182Source | 46,982Source | 29,130Source | 59,032Source | 45,158Source | 156,703Source | 56,925Source | 43,369Source | 167,114Source | 158,451Source |
| Accounts Payable, CurrentUSD | 4,771,026Source | 4,055,332Source | 4,671,952Source | 4,315,010Source | 4,205,371Source | 4,707,393Source | 3,786,134Source | 3,560,474Source | 5,362,604Source | 4,197,561Source | 3,925,438Source | 2,459,063Source |
| Operating Lease, Liability, NoncurrentUSD | 226,532Source | 281,437Source | 179,721Source | 240,903Source | — | 195,957Source | 254,989Source | — | 211,873Source | 268,798Source | 29,130Source | 27,396Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 716,878Source | 1,022,373Source | 619,270Source | 645,567Source | 1,319,201Source | 643,503Source | 818,254Source | 1,710,815Source | 619,242Source | 1,168,786Source | 1,540,607Source | 1,531,238Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 1,751,854Source | — | — | 2,151,243Source | — | — | 2,556,384Source | — | — | 5,005,598Source | — |
| Deferred Revenue, CurrentUSD | — | 283,571Source | — | — | 258,872Source | — | — | 272,681Source | — | — | 415,771Source | 132,335Source |
| Additional Paid in Capital, Common Stock | —Source | — | — | —Source | — | — | —Source | — | — | — | — | — |
| Long-term Debt, Current Maturities | — | —Source | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,028Source | 15,901Source | 21,266Source | 249,675Source | 459,666Source | 678,613Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 84,918Source | -751,943Source | -1,336,475Source | 903,329Source | -564,488Source | -1,297,946Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | -45,110Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -393,686Source | -411,427Source | 1,240,043Source | 272,123Source | 1,466,375Source | 1,626,385Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,361,846Source | -1,095,845Source | -4,240,608Source | -8,263,713Source | -5,807,550Source | -5,817,720Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -700,000Source | — | -1,000,454Source | 1,979,554Source | -7,228,383Source | -3,191,190Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 454Source | 31,546Source | 19,478Source | 215,504Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 10,243,489Source | 5,818,901Source | 70,889Source | -3,421,359Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,782,758Source | 1,751,854Source | 4,414,364Source | 588,775Source | 2,818,989Source | 782,563Source | 6,880,835Source | 1,878,408Source | 2,343,666Source | 15,308,710Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 1,946Source | 1,948Source | 33,751Source | 16,001Source | 161,579Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 77,384Source |
| Amortization of Intangible AssetsUSD | — | — | 47,889Source | 47,889Source | — | — | — | 47,888Source | 191,555Source | 191,555Source | 49,520Source | 1,182,766Source |
| Capitalized Computer Software, AmortizationUSD | — | — | 392,718Source | 478,384Source | — | — | 133,536Source | 367,718Source | 1,470,873Source | 2,036,981Source | 1,948,085Source | 1,182,766Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 1,751,854Source | — | — | — | — | — | — | 5,005,598Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 680Source | 0Source | — |
| DepreciationUSD | — | — | 17,123Source | 16,506Source | 2,123Source | 17,125Source | 2,409Source | 17,103Source | 68,474Source | 65,712Source | 117,543Source | 22,433Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -58Source | — | — |
| General and Administrative ExpenseUSD | — | — | 864,061Source | 892,712Source | 442,508Source | 948,376Source | 680,415Source | 758,666Source | 3,472,233Source | 6,067,276Source | 5,935,092Source | 6,932,727Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 2Source | 7,364Source | — | — | — | 1,946Source | 1,949Source | 173,771Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 6,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 291Source | 1,235Source | 270Source | 398Source | 291Source | 2,788Source | 3,748Source | — | — | — |
| LitigationSettlementLossUSD | — | — | — | — | — | — | — | 50,000Source | 215,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,780,648Source | -1,439,853Source | -1,362,811Source | -1,047,243Source | -2,275,221Source | -1,658,396Source | -10,487,532Source | -12,497,805Source | -11,099,488Source | -10,245,922Source |
| Nonoperating Income (Expense)USD | — | — | 49,574Source | 265,551Source | 175Source | 774,183Source | 263,182Source | -20,007Source | -1,509,613Source | 230,240Source | 69,861Source | -59,840Source |
| Other Nonoperating Income (Expense)USD | — | — | 47,216Source | 271,680Source | -95Source | 764,165Source | 264,144Source | -2,309Source | -1,503,443Source | 406,181Source | -39,104Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 3,999,574Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | — | — | — | 70,889Source | 78,641Source |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 106,592Source | 2,661,936Source | 151,940Source | 713,135Source | 156,009Source | 1,057,510Source | 1,928,998Source | 9,291,115Source | 9,928,184Source | 10,402,303Source |
| Cost of RevenueUSD | — | — | 204,593Source | 1,554,159Source | 83,290Source | 444,177Source | 84,410Source | 657,279Source | 1,904,888Source | 5,302,712Source | 4,820,268Source | 4,756,965Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -2,830,222Source | -1,705,404Source | -1,362,986Source | -1,821,426Source | -2,538,403Source | -1,638,389Source | -8,977,919Source | -12,728,045Source | -11,169,349Source | -10,186,082Source |
| Other Nonoperating Income (Expense)USD | — | — | 47,216Source | 271,680Source | -95Source | 764,165Source | 264,144Source | -2,309Source | -1,503,443Source | 406,181Source | -39,104Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,780,648Source | -1,439,853Source | -1,362,811Source | -1,047,243Source | -2,275,221Source | -1,658,396Source | -10,487,532Source | -12,497,805Source | -11,099,488Source | -10,245,922Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.48Source | -2.1Source | -0.98Source | -16.78Source | -6.66Source | -28.55Source | -2.28Source | -17.58Source | -1.23Source | -1.16Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.48Source | -2.1Source | -0.98Source | -16.78Source | -6.66Source | -28.55Source | -2.28Source | -17.58Source | -1.23Source | -1.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 5,839,580Source | 687,147Source | 1,394,482Source | 62,424Source | 341,377Source | 58,078Source | 4,602,461Source | 710,852Source | 9,041,341Source | 8,844,307Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 5,839,580Source | 687,147Source | 1,394,482Source | 62,424Source | 341,377Source | 58,078Source | 4,602,461Source | 710,852Source | 9,041,341Source | 8,844,307Source |
| Interest Expense (non-operating)USD | — | — | 2Source | 7,364Source | — | — | — | 1,946Source | 1,949Source | 173,771Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 47,889Source | 47,889Source | — | — | — | 47,888Source | 191,555Source | 191,555Source | 49,520Source | 1,182,766Source |
| Capitalized Computer Software, AmortizationUSD | — | — | 392,718Source | 478,384Source | — | — | 133,536Source | 367,718Source | 1,470,873Source | 2,036,981Source | 1,948,085Source | 1,182,766Source |
| Costs and ExpensesUSD | — | — | 2,936,814Source | 4,367,340Source | 1,514,926Source | 2,534,561Source | 2,694,412Source | 2,695,899Source | 10,906,917Source | 22,019,160Source | 21,097,533Source | 20,588,385Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 135,945Source | 432,709Source | 1,730,902Source | 2,294,248Source | — | — |
| General and Administrative ExpenseUSD | — | — | 864,061Source | 892,712Source | 442,508Source | 948,376Source | 680,415Source | 758,666Source | 3,472,233Source | 6,067,276Source | 5,935,092Source | 6,932,727Source |
| Interest ExpenseUSD | — | — | — | 7,364Source | — | — | — | — | — | — | 16,001Source | 238,963Source |
| Interest Income, OtherUSD | — | — | — | 1,235Source | — | — | 291Source | 2,788Source | 3,748Source | 44,133Source | 339,750Source | 169,345Source |
| Investment Income, InterestUSD | — | — | 291Source | 1,235Source | 270Source | 398Source | 291Source | 2,788Source | 3,748Source | — | — | — |
| LitigationSettlementLossUSD | — | — | — | — | — | — | — | 50,000Source | 215,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 49,574Source | 265,551Source | 175Source | 774,183Source | 263,182Source | -20,007Source | -1,509,613Source | 230,240Source | 69,861Source | -59,840Source |
| Other ExpensesUSD | — | — | — | — | — | — | 114,013Source | 177,649Source | 688,942Source | 1,493,310Source | — | — |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | 1,493,310Source | 1,618,833Source | 1,473,520Source |
| Selling and Marketing ExpenseUSD | — | — | 1,140,902Source | 631,625Source | 544,465Source | 258,382Source | 1,542,297Source | 347,140Source | 2,295,501Source | 4,945,269Source | 3,955,974Source | 3,445,344Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Interest Expense, Debt | — | — | — | —Source | — | — | — | — | — | — | — | — |
Offerings
Registration 333-297001
- Gross proceeds
- 4999998.9
- Net proceeds
- 4799998.94
- Deal price
- 1.3
- Shares
- 3846153
- Offering price
- $1.30
- Ticker
- ISPC
Underwriters: E.F. Hutton
Registration 333-296512
Registration 333-292804
Registration 333-289725
Registration 333-286958
- Net proceeds
- 0.6719
- Deal price
- 0.7
- Ticker
- ISPC
Filing attachments
ea031086601ex99-1.htm · 8-K · 2026-11-05
Exhibit 99.1 iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products New Agentic AI tools for protein discovery and disease trend prediction take iSpecimen beyond its biospecimen marketplace WOBURN, MA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace connecting scientists who need biospecimens for medical research with a network of healthcare specimen prov…
Read attachment ↗ea030100601ex4-1.htm · 8-K · 2026-08-07
EX-4.1 2 ea030100601ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT iSpecimen Inc. Warrant Shares: _______ Initial Exercise Date: ______, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (th…
Read attachment ↗ea030100601ex99-1.htm · 8-K · 2026-08-07
EX-99.1 5 ea030100601ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, ANNOUNCING THE PRICING OF THE OFFERING Exhibit 99.1 iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced tod…
Read attachment ↗ea030100601ex99-2.htm · 8-K · 2026-08-07
EX-99.2 6 ea030100601ex99-2.htm PRESS RELEASE DATED AUGUST 7, 2026, ANNOUNCING THE CLOSING OF THE OFFERING Exhibit 99.2 iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced tod…
Read attachment ↗ea029703201ex4-4.htm · S-1/A · 2026-07-06
Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT iSpecimen Inc. Warrant Shares: _______ Initial Exercise Date: ______, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is e…
Read attachment ↗ea029014301ex4-1.htm · 8-K · 2026-05-13
EX-4.1 2 ea029014301ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 iSPECIMEN INC. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER …
Read attachment ↗